BG63451B1 - Фармацевтични форми със забавено освобождаване съдържащи мизоластин - Google Patents

Фармацевтични форми със забавено освобождаване съдържащи мизоластин Download PDF

Info

Publication number
BG63451B1
BG63451B1 BG102692A BG10269298A BG63451B1 BG 63451 B1 BG63451 B1 BG 63451B1 BG 102692 A BG102692 A BG 102692A BG 10269298 A BG10269298 A BG 10269298A BG 63451 B1 BG63451 B1 BG 63451B1
Authority
BG
Bulgaria
Prior art keywords
sustained release
pharmaceutical formulation
formulation according
release pharmaceutical
misolastin
Prior art date
Application number
BG102692A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102692A (en
Inventor
Maryvonne Chariot
Gareth Lewis
Jean Montel
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo filed Critical Synthelabo
Publication of BG102692A publication Critical patent/BG102692A/xx
Publication of BG63451B1 publication Critical patent/BG63451B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG102692A 1996-03-04 1998-08-12 Фармацевтични форми със забавено освобождаване съдържащи мизоластин BG63451B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9602662A FR2745500B1 (fr) 1996-03-04 1996-03-04 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
PCT/FR1997/000355 WO1997032584A1 (fr) 1996-03-04 1997-02-28 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine

Publications (2)

Publication Number Publication Date
BG102692A BG102692A (en) 1999-04-30
BG63451B1 true BG63451B1 (bg) 2002-02-28

Family

ID=9489799

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102692A BG63451B1 (bg) 1996-03-04 1998-08-12 Фармацевтични форми със забавено освобождаване съдържащи мизоластин

Country Status (35)

Country Link
US (2) US6165507A (pl)
EP (1) EP0906101B1 (pl)
JP (2) JP2000512617A (pl)
KR (1) KR100369888B1 (pl)
CN (1) CN1112929C (pl)
AR (1) AR006082A1 (pl)
AT (1) ATE219365T1 (pl)
AU (1) AU725494B2 (pl)
BG (1) BG63451B1 (pl)
BR (1) BR9707827A (pl)
CA (1) CA2247405C (pl)
CO (1) CO4780020A1 (pl)
CY (1) CY2293B1 (pl)
CZ (1) CZ291418B6 (pl)
DE (1) DE69713505T2 (pl)
DK (1) DK0906101T3 (pl)
EE (1) EE03511B1 (pl)
ES (1) ES2177942T3 (pl)
FR (1) FR2745500B1 (pl)
HK (1) HK1017999A1 (pl)
HU (1) HU227472B1 (pl)
IL (1) IL126050A (pl)
IN (1) IN187739B (pl)
NO (1) NO315841B1 (pl)
NZ (1) NZ331947A (pl)
OA (1) OA10854A (pl)
PL (1) PL189813B1 (pl)
PT (1) PT906101E (pl)
RU (1) RU2173997C2 (pl)
SK (1) SK282112B6 (pl)
TR (1) TR199801574T2 (pl)
TW (1) TW491711B (pl)
UA (1) UA49004C2 (pl)
WO (1) WO1997032584A1 (pl)
ZA (1) ZA971830B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002087960A (ja) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd 徐放性錠剤
EP1322158B1 (en) * 2000-10-02 2012-08-08 USV Ltd. Sustained release pharmaceutical compositions containing metformin and method of their production
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
NZ542176A (en) * 2003-03-04 2007-12-21 Nostrum Pharmaceuticals Inc Control release formulation containing a hydrophobic material as the sustained release agent
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
EP2309985B1 (en) 2008-07-28 2018-03-14 Takeda Pharmaceutical Company Limited Pharmaceutical composition
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
JPS62283926A (ja) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd 塩酸ニカルジピン持続性組成物
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
JP3195391B2 (ja) * 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤

Also Published As

Publication number Publication date
TR199801574T2 (xx) 1998-11-23
HUP9902458A3 (en) 2002-11-28
ATE219365T1 (de) 2002-07-15
DE69713505T2 (de) 2003-02-13
CO4780020A1 (es) 1999-05-26
CA2247405C (en) 2004-04-20
WO1997032584A1 (fr) 1997-09-12
PL328763A1 (en) 1999-02-15
NZ331947A (en) 2000-03-27
JP2007182451A (ja) 2007-07-19
EP0906101B1 (fr) 2002-06-19
NO984035D0 (no) 1998-09-02
AU725494B2 (en) 2000-10-12
HUP9902458A2 (hu) 2000-05-28
FR2745500B1 (fr) 1998-04-03
SK282112B6 (sk) 2001-11-06
KR19990087387A (ko) 1999-12-27
BG102692A (en) 1999-04-30
IL126050A0 (en) 1999-05-09
CY2293B1 (en) 2003-07-04
EE03511B1 (et) 2001-10-15
TW491711B (en) 2002-06-21
NO984035L (no) 1998-10-22
AR006082A1 (es) 1999-08-11
UA49004C2 (uk) 2002-09-16
PL189813B1 (pl) 2005-09-30
IL126050A (en) 2004-05-12
HK1017999A1 (en) 1999-12-10
CA2247405A1 (en) 1997-09-12
AU1930097A (en) 1997-09-22
ES2177942T3 (es) 2002-12-16
DE69713505D1 (de) 2002-07-25
ZA971830B (en) 1997-09-04
FR2745500A1 (fr) 1997-09-05
DK0906101T3 (da) 2002-10-14
JP2000512617A (ja) 2000-09-26
SK121098A3 (en) 1999-01-11
PT906101E (pt) 2002-09-30
OA10854A (fr) 2003-02-05
RU2173997C2 (ru) 2001-09-27
US20050202089A1 (en) 2005-09-15
EP0906101A1 (fr) 1999-04-07
BR9707827A (pt) 1999-07-27
CN1212624A (zh) 1999-03-31
HU227472B1 (en) 2011-07-28
NO315841B1 (no) 2003-11-03
CN1112929C (zh) 2003-07-02
IN187739B (pl) 2002-06-15
EE9800275A (et) 1999-02-15
US6165507A (en) 2000-12-26
CZ291418B6 (cs) 2003-03-12
KR100369888B1 (ko) 2003-05-17
CZ279198A3 (cs) 1999-01-13

Similar Documents

Publication Publication Date Title
US6677342B2 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US7618649B2 (en) Extended release oral dosage composition
JP2007182451A (ja) ミゾラスチンを含有する徐放性医薬製剤
US7226614B2 (en) Tablet comprising cetirizine and pseudoephedrine
SK283633B6 (sk) Farmaceutický prípravok obsahujúci ACE inhibítor ramipril a dihydropyridínovú zlúčeninu, spôsob výroby farmaceutického prípravku a jeho použitie
BG64168B1 (bg) Бързоразтворима таблета на галантамин хидробромид
RU2286784C2 (ru) Таблетка, содержащая цетиризин и псевдоэфедрин
NZ220769A (en) Compositions of ketotifen (4-(1-methyl-4-piperidylidene)- 4h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-9(h)-one)
US8105627B2 (en) Extended release venlafaxine tablet formulation
EP3087979A1 (en) Sustained-release pharmaceutical composition containing acebrophylline and hydrophobic sustained-release agent
US20050171119A1 (en) Pharmaceutical formulations with modified release
KR20210012082A (ko) 미라베그론 및 탐스로신을 포함하는 약학 조성물